ASH News Daily - Sunday, December 11, 2011 - (Page A-18)
Page A–18
®
Iron
«« From Page A-15
the hepcidin-ferroportin system results
in iron overload disorders (decreased
hepcidin) and iron restrictive
disorders (excess hepcidin).
In keeping with the theme of
iron and its role in human diseases,
Dr. Mark Fleming of Children’s
Hospital Boston concluded
by discussing the congential sideroblastic
anemias (CSAs) and the
genetics of these rare disorders.
The CSAs share the morphologic
finding of mitochondrial iron deposition
in erythroblasts. In approximately
two-thirds of cases of
CSAs, a specific molecular diagnosis
can be made. The defective
genes in CSAs often have a role in
mitochondrial heme or iron-sulfur
cluster biosynthesis or mitochondrial
translation/protein expression.
In some cases, the genetic
defect can help direct specific therapy.
Lastly, in discussing more
recent data, Dr. Fleming stated
that “myelodysplastic syndromes
Correction
In yesterday’s B Section cover article, we incorrectly stated that Dr.
Bob Lowenberg was an Associate Editor of Blood. We regret the error.
with ringed sideroblasts (such as
refractory anemia with ringed sideroblasts)
almost always have mutations
in proteins associated with
the mRNA splicing machinery.”
You may want to stick around for
the Scientific Program session “Iron
and Heme Sensing in Red Cells and
Anemia” offered after the above
education session today at 9:30 a.m.
(Douglas Pavilion D, Manchester
Grand Hyatt); this session will also
discuss iron balance, new discoveries
in hepcidin modulation secondary
to systemic cues, and the role of
a heme-regulated translational inhibitor
as a modifier of red cell disorders
in humans. Dr. Jan Abkowitz
of the University of Washington,
Seattle, will address the question,
“Why should developing erythroid
cells need to export heme when
their adequate supply in mature red
cells is so critical?” and share exciting
results of recent genetic studies
in this area during the program.
Drs. Panepinto and Brandow indicated
no relevant conflicts of interest.
ASH NEWS DAILY
Acronyms
«« From Page A-9
and feel that the next steps are “to
design and conduct clinical trials
to validate and prove the concept
of personalized medicine, so that
the molecular tests and treatment
will be reimbursed and the personalized
approach will become the
standard of care.” How exciting!
Lastly, Dr. Petri Bono from
Helsinki University Central Hospital
and University of Helsinki,
Finland, will present more practice-changing
data. He will show
the results of the prospective,
randomized, multicenter, phase
III trial showing that three years
of treatment with imatinib after
surgery in patients with high-risk
Sunday, December 11, 2011
gastrointestinal stromal tumors
(GIST) improved overall and recurrence-free
survival compared
with one year of treatment. This
is the first example of long-term
adjuvant therapy with a targeted
small molecule tyrosine kinase
inhibitor. With a tolerable side effect
profile, 36 months of adjuvant
imatinib is expected to become the
new standard of care following
curative surgery for GIST.
Along with the reality of personalized
medicine and a survival
advantage demonstrated simply
by extending targeted therapy for
patients with GIST, this is sure to
be a most exciting session.
Dr. Landau indicated no relevant
conflicts of interest.
Access the Entire Blood Website on
Your iPhone, Blackberry, or Android
T
he mobile-friendly version of the Blood website
includes all of the online content such as
current issues, First Edition papers, full ar-
chive, and more. You will have the ability to do fulltext
search of any article and to submit your paper
to Blood.
To access the new mobile-friendly site, go to http://
bloodjournal.org from your device’s Web browser.
http://www.bloodjournal.org
http://www.bloodjournal.org
Table of Contents for the Digital Edition of ASH News Daily - Sunday, December 11, 2011
ASH News Daily - Sunday, December 11, 2011
https://www.nxtbookmedia.com